$300 to Learn Risk of Prostate Cancer
By Gina Kolata,
New York Times
| 01. 17. 2008
A combination of common and minor variations in five regions of DNA can help predict a man’s risk of getting prostate cancer, researchers reported Wednesday.
A company formed by researchers at Wake Forest University School of Medicine is expected to make the test available in a few months, said Karen Richardson, a Wake Forest spokeswoman. It should cost less than $300.
This is, some medical experts say, a first taste of what is expected to be a revolution in medical prognostication. The results, they agree, are clear. But the question is what happens next. And will patients be helped or harmed? Because the new test — which will analyze DNA in blood or saliva samples and is to be offered by ProActive Genomics — cannot predict which men will get aggressive cancers, it could lead to more screening and unnecessary surgery and complications. But, proponents say, it could also help men decide whether they want aggressive screening in the first place.
see moreThe researchers found that about 90 percent of the men in the study had one or more of the...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jonquilyn Hill, Vox | 10.18.2026
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...